Table 1. Clinicopathological characteristics in 584 patients by LVSI status.
| Characteristic | LVSI negative (n=513) | LVSI positive (n=71) | p value | ||
|---|---|---|---|---|---|
| Age | 55.03±9.51 | 56.42±8.39 | 0.200 | ||
| BMI (kg/m2) | 26.41±4.52 | 25.70±3.68 | 0.205 | ||
| Gravidity | 2.48±1.42 | 2.37±1.52 | 0.568 | ||
| Parity | 1.41±0.98 | 1.40±0.92 | 0.927 | ||
| Diabetes history | 0.001 | ||||
| No | 410 (79.92) | 44 (61.97) | |||
| Yes | 103 (20.08) | 27 (38.03) | |||
| Hypertension history | 0.554 | ||||
| No | 299 (58.28) | 44 (61.97) | |||
| Yes | 214 (41.72) | 27 (38.03) | |||
| Familial tumor history | 0.916 | ||||
| No | 431 (84.02) | 60 (84.51) | |||
| Yes | 82 (15.98) | 11 (15.49) | |||
| Pre-surgery CA125 (U/mL) | 37.22±77.96 | 53.82±111.61 | 0.132 | ||
| Pre-surgery CA19-9 (U/mL) | 35.50±84.33 | 35.05±65.52 | 0.970 | ||
| Stage | <0.001 | ||||
| Early (I–II) | 469 (91.42) | 52 (73.24) | |||
| Advanced (III–IV) | 44 (8.58) | 19 (26.76%) | |||
| Grade | <0.001 | ||||
| 1 | 208 (40.55) | 11 (15.49) | |||
| 2 | 250 (48.73) | 38 (53.52) | |||
| 3 | 55 (10.72) | 22 (30.99) | |||
| Tumor diameter (cm) | 2.69±2.57 | 3.84±2.44 | <0.001 | ||
| Peritoneal cytology | 1.000 | ||||
| Negative | 380 (94.53) | 50 (94.34) | |||
| Positive | 22 (5.47) | 3 (5.66) | |||
| Lymph node status | <0.001 | ||||
| Negative | 412 (94.28) | 50 (78.13) | |||
| Positive | 25 (5.72) | 14 (21.88) | |||
| Myometrial invasion | <0.001 | ||||
| <50% | 417 (81.29) | 37 (52.11) | |||
| ≥50% | 96 (18.71) | 34 (47.89) | |||
| Cervical stromal invasion | 0.009 | ||||
| No | 474 (92.40) | 59 (83.10) | |||
| Yes | 39 (7.60) | 12 (16.90) | |||
| Adnexal involvement | 0.744 | ||||
| No | 499 (97.27) | 68 (95.77) | |||
| Yes | 14 (2.73) | 3 (4.23) | |||
| Surgical specimen IHC | |||||
| ER | 0.031 | ||||
| Negative | 18 (3.68) | 7 (10.29) | |||
| Positive | 471 (96.32) | 61 (89.71) | |||
| PR | <0.001 | ||||
| Negative | 14 (2.86) | 9 (13.24) | |||
| Positive | 475 (97.14) | 59 (86.76) | |||
| P53 | 0.021 | ||||
| Negative | 217 (46.27) | 21 (31.34) | |||
| Positive | 252 (53.73) | 46 (68.66) | |||
| Ki67 (%) | 33.24±20.90 | 41.89±17.96 | 0.002 | ||
| Adjuvant therapy use | <0.001 | ||||
| No | 209 (50.36) | 14 (20.00) | |||
| Yes | 206 (49.64) | 56 (80.00) | |||
The values are presented as mean±standard deviation, or number (%), unless otherwise indicated. Bold-font values indicate p values less than 0.05, which is considered statistically significant.
BMI, body mass index; CA, carbohydrate antigen; ER, estrogen receptor; IHC, immunohistochemistry; LVSI, lymphovascular space invasion; PR, progesterone receptor.